This result reveals directly competitive binding with miR-18a between CASC2 and PIAS3 mRNA, further indicating that CASC2 functions as a ceRNA and modulates the expression of miR-18a targets in CRC to suppress cancer progression (Fig. 5D). This evidence concerns the gene PIAS3 and colorectal carcinoma.